Inovio announces positive HPV vaccine PhIIb results; NanoBio's genital herpes candidate shows efficacy in animal model;

> Inovio Pharmaceuticals ($INO) reported positive Phase IIb studies of its VGX-3100, announcing that in women with high grade cervical neoplasia, the immunotherapy produced killer T cells that were able to clear lesions and the HPV virus itself. Release

> Ann Arbor, MI-based NanoBio announced that its adjuvanted genital herpes vaccine candidate showed efficacy in guinea pigs. Statement

> IDK Biologika opened its first U.S. vaccine manufacturing plant in Rockville, MD. Announcement

> Abivax named Dr. Jean-Marc Steens its chief medical officer. Release

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.